Biotinidase deficiency: clinical and genetic studies of 38 Brazilian patients

BMC Medical Genetics

Ida VD Schwartz⁴  Sandra Leistner-Segal⁴  Pricila Bernardi⁵  Eurico C Neto¹  Reinaldo LO Filho²  Charles M Lourenço⁶  Paula FV De Medeiros⁹  Carolina FM De Souza⁴  Francisca L Carvalho⁸  Gisele R De Luca⁸  Louise LC Pinto⁸  Fernanda Sperb-Ludwig⁷  Taciane Borsatto³ 

[1] CTN Diagnósticos, Porto Alegre, Brazil;Universidade Estadual de Ciências da Saúde de Alagoas, Maceió, Brazil;BRAIN Laboratory, Center for Experimental Research (CPE), Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil;Medical Genetics Service, Hospital de Clínicas de Porto Alegre (HCPA), Rua Ramiro Barcelos, Porto Alegre, 90035-903, Brazil;Hospital Universitário-Universidade Federal de Santa Catarina, Florianópolis, Brazil;Medical Genetics Service, Hospital das Clínicas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil;Gene Therapy Center, CPE, HCPA, Porto Alegre, Brazil;Hospital Infantil Joana de Gusmão, Florianópolis, Brazil;Universidade Federal de Campina Grande, Campina Grande, Brazil

关键词: Brazil;    Neonatal screening;    Genetic variants;    Low biotinidase;   

Others  :  1090804
DOI  :  10.1186/s12881-014-0096-3

 received in 2014-04-08, accepted in 2014-08-05,  发布年份 2014

【 摘 要 】

Background

Biotinidase deficiency (BD) is an inborn error of metabolism in which some genetic variants correlate with the level of enzyme activity. Biotinidase activity, however, may be artifactually low due to enzyme lability, premature birth, and jaundice; this hinders both phenotypic classification and the decision to implement therapy. This study sought to characterize the clinical and genetic profile of a sample of Brazilian patients exhibiting reduced biotinidase activity.

Methods

This observational, multicenter study used a convenience sampling strategy, with sequencing of exons 2, 3, and 4 of the BTD gene.

Results

The sample comprised 38 individuals with biochemical phenotypes defined a priori on the basis of biotinidase activity in serum/plasma (2 with profound deficiency, 9 with partial deficiency, 15 heterozygous, 1 borderline between partial deficiency and heterozygosity, 2 borderline between heterozygous and normal) or dried blood spot sample (n = 9, all with unspecified deficiency). Most patients were from Southern Brazil (n = 29/38) and were identified by neonatal screening (n = 33/38). Parental consanguinity was reported in two cases. The most commonly found genetic variants were c.1330G > C (p.D444H), c.755A > G (p.D252G), and c.[511G > A;1330G > C] (p.[A171T;D444H]), with allele frequencies of 50%, 9.4%, and 5.4% respectively. Three novel pathogenic variants were identified (c.119 T > C or p.L40P, c.479G > A or p.C160Y, and c.664G > A or p.D222N). Twenty-nine patients had two pathogenic variants detected (with cis/trans status ascertained in 26/29), six had only one variant, and three had no pathogenic variants detected. Genotyping confirmed the original phenotypic classification based on enzyme activity in 16/26 cases. Three polymorphic variants were identified in control individuals, of which two were nonpathogenic (c.1171C > T or p.P391S and c.1413 T > C or p.C471C, with a frequency of 1.5% and 5.5% respectively) and one pathogenic (c.1330G > C, frequency 4%).

Conclusions

Our findings suggest that partial BD is the most common form of BD in Brazil, and expand current knowledge on the allelic heterogeneity of this condition.

【 授权许可】

   
2014 Borsatto et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hymes J, Wolf B: Biotinidase and its roles in biotin metabolism. Clin Chim Acta 1996, 255:1-11.
• [2]Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL: Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. Clin Chim Acta 1983, 131:273-281.
• [3]Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL, Parker WD, Howell DM, Hurst DL: Phenotypic variation in biotinidase deficiency. J Pediatr 1983, 103:233-237.
• [4]Bay LB, de Pinho S, Eiroa HD, Otegui I, Rodriguez R: [The importance of a law on time: presentation of a girl with biotinidase deficiency who was not picked up through the neonatal screening]. Arch Argent Pediatr 2010, 108:e13-e16.
• [5]Wastell HJ, Bartlett K, Dale G, Shein A: Biotinidase deficiency: a survey of 10 cases. Arch Dis Child 1988, 63:1244-1249.
• [6]Wolf B: Clinical issues and frequent questions about biotinidase deficiency. Mol Genet Metab 2010, 100:6-13.
• [7]Wolf B: Biotinidase deficiency: new directions and practical concerns. Curr Treat Options Neurol 2003, 5:321-328.
• [8]Suormala T, Wick H, Baumgartner ER: Low biotinidase activity in plasma of some preterm infants: possible source of false-positive screening results. Eur J Pediatr 1988, 147:478-480.
• [9]Schulpis KH, Gavrili S, Tjamouranis J, Karikas GA, Kapiki A, Costalos C: The effect of neonatal jaundice on biotinidase activity. Early Hum Dev 2003, 72:15-24.
• [10]Cowan TM, Blitzer MG, Wolf B: Technical standards and guidelines for the diagnosis of biotinidase deficiency. Genet Med 2010, 12:464-470.
• [11]Wolf B: Biotinidase Deficiency. In GeneReviews™ [Internet]. Edited by Pagon RA, Adam MP, Bird TD, Ardinger HH, Dolan CR, Fong CT, Smith RJH, Stephens K. Seattle (WA), University of Washington, Seattle; 2000. Updated 2013 Dec 5
• [12]Swango KL, Demirkol M, Huner G, Pronicka E, Sykut-Cegielska J, Schulze A, Mayatepek E, Wolf B: Partial biotinidase deficiency is usually due to the D444H mutation in the biotinidase gene. Hum Genet 1998, 102:571-575.
• [13]Wolf B: Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”. Genet Med 2012, 14:565-575.
• [14]Wolf B, Jensen KP, Barshop B, Blitzer M, Carlson M, Goudie DR, Gokcay GH, Demirkol M, Baykal T, Demir F, Quary S, Shih LY, Pedro HF, Chen TH, Slonim AE: Biotinidase deficiency: novel mutations and their biochemical and clinical correlates.Hum Mutat 2005, 25:413.
• [15]Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
• [16]Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081.
• [17]Luz GS, Carvalho MD, Pelloso SM, Higarashi IH: [Prevalence of diseases diagnosed by the Program of Neonatal Screening in Maringa, Parana, Brazil: 2001–2006]. Rev Gaucha Enferm 2008, 29:446-453.
• [18]Neto EC, Schulte J, Rubim R, Lewis E, DeMari J, Castilhos C, Brites A, Giugliani R, Jensen KP, Wolf B: Newborn screening for biotinidase deficiency in Brazil: biochemical and molecular characterizations. Braz J Med Biol Res 2004, 37:295-299.
• [19]Pinto AL, Raymond KM, Bruck I, Antoniuk SA: [Prevalence study of biotinidase deficiency in newborns]. Rev Saude Publica 1998, 32:148-152.
• [20]Wolf B: Worldwide survey of neonatal screening for biotinidase deficiency. J Inherit Metab Dis 1991, 14:923-927.
• [21]Norrgard KJ, Pomponio RJ, Hymes J, Wolf B: Mutations causing profound biotinidase deficiency in children ascertained by newborn screening in the United States occur at different frequencies than in symptomatic children. Pediatr Res 1999, 46:20-27.
• [22]Norrgard KJ, Pomponio RJ, Swango KL, Hymes J, Reynolds T, Buck GA, Wolf B: Double mutation (A171T and D444H) is a common cause of profound biotinidase deficiency in children ascertained by newborn screening the the United States. Mutations in brief no. 128. Online.Hum Mutat 1998, 11:410.
• [23]Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF: Carrier testing for severe childhood recessive diseases by next-generation sequencing.Sci Transl Med 2011, 3:65ra64.
• [24]Milankovics I, Nemeth K, Somogyi C, Schuler A, Fekete G: High frequencies of biotinidase (BTD) gene mutations in the Hungarian population. J Inherit Metab Dis 2010, 33(Suppl 3):S289-S292.
• [25]Thodi G, Schulpis KH, Molou E, Georgiou V, Loukas YL, Dotsikas Y, Papadopoulos K, Biti S: High incidence of partial biotinidase deficiency cases in newborns of Greek origin. Gene 2013, 524:361-362.
• [26]Wolf B, Jensen K, Huner G, Demirkol M, Baykal T, Divry P, Rolland MO, Perez-Cerda C, Ugarte M, Straussberg R, Basel-Vanagaite L, Baumgartner ER, Suormala T, Scholl S, Das AM, Schweitzer S, Pronicka E, Sykut-Cegielska J: Seventeen novel mutations that cause profound biotinidase deficiency. Mol Genet Metab 2002, 77:108-111.
• [27]Pomponio RJ, Reynolds TR, Cole H, Buck GA, Wolf B: Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency. Nat Genet 1995, 11:96-98.
• [28]Pomponio RJ, Reynolds TR, Mandel H, Admoni O, Melone PD, Buck GA, Wolf B: Profound biotinidase deficiency caused by a point mutation that creates a downstream cryptic 3’ splice acceptor site within an exon of the human biotinidase gene. Hum Mol Genet 1997, 6:739-745.